Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D617 and CYP2D629, When Compared with Normal Metabolizers.

This study investigated the differences in the pharmacokinetics (PK) of dextromethorphan and desipramine in healthy African volunteers to understand the effect of allelic variants of the human cytochrome P450 2D6 (CYP2D6) enzyme, namely the diplotypes of CYP2D6*1/*2 (*1*1, *1*2, *2*2) and the genoty...

Descripción completa

Detalles Bibliográficos
Publicado en:	Journal of Clinical Pharmacology Vol. 64; no. 5; pp. 578 - 590
Autores principales:	Marasanapalle, Venugopal P., Masimirembwa, Collen, Sivasubramanian, Rama, Sayyed, Sarfaraz, Weinzierl‐Hinum, Armin, Mehta, Dheeraj, Kapungu, Nyasha Nicole, Kanji, Comfort, Thelingwani, Roslyn, Zack, Julia
Formato:	research tables/charts Journal Article
Publicado:	Wiley-Blackwell May2024
Acceso en línea:	Ver este registro en EBSCOhost

Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers.

Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D617 and CYP2D629, When Compared with Normal Metabolizers.